Exhibit 99.1 DYADIC REPORTS 2023 FULL YEAR RESULTS AND RECENT COMPANY PROGRESS ● Closed a $6.0 million convertible note in a private placement, with a conversion price of $1.79 and no warrants ● Reported positive topline data from First-In-Human Phase 1 trial demonstrated clinical safety and antibody response for DYAI-100 a recombinant protein receptor binding domain (RBD) booster vaccine candidate for protection against COVID-19 infection ● Entered into several fully funded vaccine and antibody projects co ...